Today's Healthcare Pulse
Allogene Therapeutics CEO David Chang to step down
Allogene Therapeutics announced that chief executive David Chang will leave his role. The news was reported by STAT+ and echoed in a follow‑up piece covering broader pharma updates.
Also developing:
By the numbers: Boston Scientific invests $1.5B for 34% stake in MiRus
Sex, Racial Disparities Persist Across Melanoma Care Continuum
Two posters presented at the 2026 American Academy of Dermatology meeting reveal enduring melanoma inequities. Men experience a 50% higher incidence (30.8 vs 19.8 per 100,000) and a 1.43‑fold higher mortality‑to‑incidence ratio than women, with some western counties showing more than double the disparity. Analysis of 47,117 melanoma deaths shows African American and Asian patients are significantly more likely to die in inpatient or emergency settings and far less likely to die at home or in hospice. The findings highlight gaps from early detection through end‑of‑life care.
First-Ever WHO Forum Unites 800+ Collaborating Centres for Stronger Scientific Collaboration
The World Health Organization convened its inaugural Global Forum of Collaborating Centres, drawing more than 800 institutions from over 80 countries. Delegates highlighted emerging health threats and pledged to move beyond isolated projects toward integrated, dynamic partnerships. A new Collaborative...
Re: Doctors’ Distinct Work and Professional Role Can’t Be Parcelled Into Generic Tasks for “Tiers” Of Healthcare Staff
Retired GP Ann Bowman wrote to the BMJ in support of a recent article warning against overly generic task‑allocation across healthcare tiers. She acknowledges the pitfalls of "taskification" but points out that resident doctors still perform routine procedures such as...
Recovery Works When Coverage Does: The Lifesaving Impact of Medicare’s IOP Expansion
In 2024 Medicare closed a long‑standing coverage gap by adding an intensive outpatient program (IOP) benefit for mental health and substance‑use disorders, including opioid use disorder. Early data show IOP participants improved their BARC‑10 recovery scores by 4.56 points and...
Meta-Analysis Supports Efficacy, Cost Savings of In-Home Vitiligo Therapy
A new meta‑analysis of four controlled studies confirms that home‑based narrowband UVB phototherapy delivers comparable repigmentation outcomes to traditional in‑office treatment for vitiligo. The analysis, covering 148 patients using home devices and 143 receiving clinic care, found odds ratios of...
Right‑to‑Repair Settlement Shows Interoperability Beats Antitrust Breakups
Interoperability wins come in all shapes and sizes. This week's shape is... tractor? John Deere just agreed to a $99 million right-to-repair settlement that includes a 10-year court-supervised mandate to open its diagnostic tooling to farmers and independent repair shops. The...
Avalyn Targets Hard-to-Treat Lung Disease, Prepares IPO
Chasing a tough-to-treat lung disease, Avalyn plans an IPO https://t.co/743svTKTS4 by @gwendolynawu #IPO $AVLN $BMY $ABBV
Athenahealth Targets AI-Driven Patient Discovery with New Rater8 Reputation Management Integration
athenahealth has embedded rater8’s AI‑powered reputation management directly into its athenaOne EHR platform, allowing ambulatory practices to capture reviews, monitor sentiment, and manage directory listings without leaving their clinical workflow. The move is part of athenahealth’s new Alliance Partnerships program,...
Eli Lilly's GLP-1 Pill Ignites Rivalry with Novo
Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk https://t.co/zM6udFvuNE by Kristin Jensen $LLY $NVO #obesity
Most Health AI Users Don’t Rate Chatbots as Highly Accurate: Poll
A recent Pew poll of over 5,000 U.S. adults shows that while more than 20% occasionally use AI chatbots for health questions, only 18% consider the information very or extremely accurate. By contrast, 65% trust their providers for accurate advice,...
CDC Study Shows COVID Shot Benefits; Trump Official Blocks Release
A CDC‑vetted study found that the 2025‑2026 COVID‑19 vaccine cut urgent‑care visits by roughly 50% and hospitalizations by 55% among healthy adults. The research was slated for publication in the MMWR on March 19 but was halted by acting CDC...
Medline Recalls Millions of Devices Due to Safety Risk—FDA Threatens ‘Regulatory Action’ in Warning Letter
Medline, an Illinois‑based medical supplier that went public in December 2025, is recalling more than 4 million NAMIC angiographic control syringes and over 1 million procedure kits because of a loose‑connection defect that can cause air embolism or clinician exposure. The FDA...
Court Blocks Tennessee From Dictating Employer Pharmacy Benefit Design
A federal appeals court ruled that Tennessee's pharmacy‑benefit‑manager statutes are preempted by ERISA, reaffirming that states cannot control the design of self‑funded health‑plan pharmacy networks. The Sixth Circuit found the laws crossed three of four preemption lines by forcing open...
Talkiatry Launches Talkiatry Connect for Cloud-Based EMR Psychiatric Referrals
Talkiatry, the largest private employer of psychiatrists in the United States, has introduced Talkiatry Connect, a browser‑based overlay that integrates directly with more than 30 cloud‑based EMR systems. The tool places a small icon in the clinician’s workflow; when clicked,...
B‑cell Reboot Shows Promise Across Multiple Autoimmune Diseases
More success for rebooting B cells towards cure of different autoimmune diseases beyond lupus, MS and others https://t.co/sFGMiFeiEF https://t.co/Dbvca9eox8
British Heart Foundation Receives Largest Donation
The British Heart Foundation received a £6 million (≈$7.7 million) donation from the Garfield Weston Foundation, the charity’s largest single gift ever. The money will bolster the BHF’s Centre of Research Excellence in Advanced Cardiac Therapies, a joint venture with the Medical...
Re: Glucagon-Like Peptide-1 Receptor Agonists and Risk of Substance Use Disorders Among US Veterans with Type 2 Diabetes: Cohort Study
A BMJ cohort study emulating a target trial found that US veterans with type 2 diabetes who were prescribed glucagon‑like peptide‑1 (GLP‑1) receptor agonists experienced significantly fewer incident substance‑use disorders (SUDs) and related adverse events compared with those on sodium‑glucose...
Low-Dose Lithium Treats Suicidal Ideation Safely
Low‑dose lithium (150‑300 mg) rapidly eliminated suicidal thoughts in young patients, with effects observed within days and sustained over years. Decades of research show lithium uniquely reduces suicide risk, outperforming alternatives like clozapine and ketamine, while its narrow therapeutic window at...
Scientists Are Finally Unlocking a Cancer Treatment’s Full Potential
German hematologist Fabian Müller applied experimental CAR‑T cell therapy to a 47‑year‑old woman suffering from three severe autoimmune diseases, achieving remission and eliminating her need for transfusions. CAR‑T, originally developed for cancer, is now delivering months‑to‑years of remission in multiple...
Sleep Disorders in Rural Appalachia Nearly 6 Times the National Average
New research published in JAMA Network Open reveals that clinical sleep disorders are dramatically more common in rural Appalachia than across the United States. Among 327 adults surveyed in 12 distressed Kentucky counties, 64.9% met criteria for insomnia and 51.3%...
STAT+: 5 Years After Lupus Breakthrough, CAR-T Is Still Surprising Autoimmunity Researchers
Five years after a pioneering CAR‑T treatment rescued a teenage lupus patient, the therapy has sustained remission and reshaped expectations for autoimmune disease management. The case, led by German rheumatologist Georg Schett, proved that engineered T cells could safely target...
Top C.D.C. Official Delays Report on Covid Shot’s Effectiveness
The CDC’s acting director, Dr. Jay Bhattacharya, postponed the release of a study that showed the Covid‑19 vaccine sharply cut hospitalizations and emergency‑room visits during the previous winter. Bhattacharya cited methodological flaws, arguing the analysis painted an inaccurate picture of...
Relacorilant (CORT125134)
Corcept Therapeutics received FDA approval for relacorilant, branded Lifyorli, in combination with nab‑paclitaxel for platinum‑resistant ovarian cancer. The oral agent is a selective glucocorticoid‑receptor antagonist that blocks cortisol signaling without binding other steroid receptors, differentiating it from older cortisol‑pathway drugs....
How to Choose the Right Home Healthcare Agency
Choosing the right home healthcare agency is critical for maintaining a loved one's safety, comfort, and quality of life. Agencies coordinate medical and personal support, ranging from skilled nursing to daily living assistance, and act as a communication bridge between...
Healthcare CIOs See AI Integration as a Competitive Necessity
A new Qventus report reveals a widening execution gap as health systems move from AI pilots to enterprise‑wide deployments. While 42% of respondents are actively rolling out AI across multiple use cases, only 4% have achieved measurable scale, and 74%...
CMS Updates Psychiatric and Rehab Payments
The Centers for Medicare & Medicaid Services (CMS) has released proposed FY 2027 payment updates for inpatient psychiatric facilities (IPFs) and inpatient rehabilitation facilities (IRFs). CMS suggests a 2.3% increase for IPFs and a 2.4% increase for IRFs, both lower than...
Siemens Healthineers, Onvida Health Sign 10-Year 'Value Partnership'
Siemens Healthineers and Onvida Health have signed a 10‑year Value Partnership to modernize the Yuma‑based health system’s imaging and therapy equipment. The agreement includes upgrades to CT, MRI, ultrasound and radiation therapy platforms and joint strategic planning with Siemens affiliate...
GoodRx Expands Access to Eli Lilly and Company’s New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More...
GoodRx announced a partnership with Eli Lilly to offer the newly FDA‑approved oral GLP‑1 drug Foundayo (orforglipron) at a self‑pay price of $149 per month. The platform is also rolling out self‑pay pricing for Lilly’s injectable Zepbound (tirzepatide) KwikPen at $299...
Long-Term Bimekizumab Data Confirm Sustained Efficacy, Consistent Safety in Hidradenitis Suppurativa: Steven Daveluy, MD
Long‑term data from the BE HEARD 1 and BE HEARD 2 trials show that 86.1% of hidradenitis suppurativa patients treated with bimekizumab remained flare‑free over a three‑year period. The biologic’s safety profile stayed consistent from week 16 through year 3, with no new signals detected. Early...
Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
Sensei Biotherapeutics announced it will present at the 25th Annual Needham Virtual Healthcare Conference on April 16, 2026. The webcast will be streamed live at 12:45 p.m. ET with a 90‑day replay window. Executives will detail the company’s lead PIKTOR program for endometrial...
NEUPATH HEALTH TO PRESENT AT THE 2026 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE
NeuPath Health Inc. announced that CEO Stephen Lemieux will present at the 2026 Bloom Burton & Co. Healthcare Investor Conference on April 22, 2026. The 30‑minute virtual session, streamed from the Metro Toronto Convention Centre, will include a live Q&A...
Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead’s First Option Target Exercise
Cartography Biosciences announced that Gilead Sciences exercised its first option to exclusively license a novel oncology target identified through Cartography’s ATLAS and SUMMIT single‑cell platforms. The target is part of a multi‑year collaboration aimed at tumor‑selective antigens in triple‑negative breast...
Eli Lilly’s Mounjaro Loses Ground to Less-Expensive Semaglutide Generics & Innovator Novo Nordisk’s Products
Eli Lilly’s tirzepatide brand Mounjaro saw sales dip to ₹114 crore in March, down from ₹135 crore in February, as low‑cost generic semaglutide entered the Indian market. The generics, launched by 13 firms across 26 SKUs, are priced 50‑80% below Novo Nordisk’s Ozempic, Wegovy...
Makena (Hydroxyprogesterone Caproate Injection) Information
The FDA’s Center for Drug Evaluation and Research has proposed withdrawing approval of Makena, a hydroxyprogesterone caproate injection originally granted accelerated approval in 2011 to reduce preterm birth risk. A confirmatory trial—four times larger than the pivotal study—failed to demonstrate...
Beyond T(11;14): Expanding Venetoclax Use in Myeloma
Venetoclax in myeloma: t(11;14) and what else? {Commentary} [Apr 2, 2026] Catherine Pellat-Deceunynck @BloodPortfolio https://t.co/Zar26htoUT #mmsm #PrecisionMedicine https://t.co/zm0Fv6GY2l
Julia Sand & The Art of Inspiration
Anthony Guerra argues that inspiration, more than strategy or coaching, is the key driver of high‑functioning teams. He illustrates this with the historical case of President Chester A. Arthur, whose unexpected moral shift followed a series of letters from Julia Sand urging him...
'The System's Broken': Minn. EMS Faces Staffing Gaps as Calls Surge
Hennepin County’s EMS is operating below minimum staffing levels even as 911 call volume climbs 26% to nearly 100,000 annually. Union records show shifts with fewer than nine paramedics on duty when over two dozen are required, and a February...
CDRH Targets Hospital Readmissions with Home Device Innovation Challenge
The FDA’s Center for Devices and Radiological Health (CDRH) launched the Reducing Readmissions through Device Innovation for the Home Innovation Challenge to spur home‑based medical devices that can lower hospital readmissions. Nine devices will be chosen by Dec 4, 2026, and the...
Hospitals That Sue You for Getting Sick
A joint GWU‑Stanford report reveals that Virginia hospitals filed 1.15 million lawsuits from 2010 to 2024, seeking $1.4 billion in unpaid medical debt. More than 400,000 wage and bank garnishments followed, with attorneys earning $87 million in fees and courts adding $46 million in...
Pure Indulgence Aesthetics - 723267 - 04/01/2026
The FDA issued a warning letter to Pure Indulgence Aesthetics after a December 2025 inspection revealed serious DSCSA violations. The spa dispensed significantly more Botox units than it purchased from AbbVie, suggesting use of unauthorized sources, and was found with...
Novartis Expands Community Health Programs to Close Gaps in Heart Disease and Cancer Care, Targeting 30+ Countries by 2030
Novartis announced a major expansion of its community health initiatives, aiming to operate in more than 30 countries by 2030. The rollout includes Inclusive Health Accelerators in five U.S. cities for breast and prostate cancer, Community Health Initiatives in at...
Trump’s Anti‑insurer Rhetoric Masks Policies Boosting Profits
The Trump administration has voiced some tough rhetoric about health insurers. But almost every major decision from Trump officials has benefited insurers and their bottom lines. The new Medicare Advantage rule is the latest example. https://t.co/ziGzSwknqK https://t.co/N3ACGahj3C
Psilocybin Mushrooms Are Going Mainstream, but Scientific Research and Regulation Lag Behind
Psilocybin mushroom use is exploding in the United States, with recent estimates showing about 11 million adults tried the substance in 2026. Legal reforms have decriminalized possession in cities like Denver and created supervised‑use programs in Oregon and Colorado, but most...
The Invisible Implementation: Why Healthcare IT Needs to Shift From Vendors to Partners
The article urges healthcare IT leaders to treat implementations as partnerships rather than vendor transactions. It stresses that successful rollouts begin weeks before the kickoff with detailed mapping of services, requirements, and dependencies. By using transparent roadmaps, parallel workstreams, and...
MediFind Becomes First Doctor Directory to Receive the Digital Medicine Society Seal
MediFind, the data‑driven online provider directory owned by Phreesia, has become the first doctor directory to earn the Digital Medicine Society (DiMe) Seal. The seal recognizes platforms that meet rigorous standards for clinical evidence, privacy, security, and usability. MediFind leverages...
EClinicalWorks Launches Production Support for CMS ‘Kill the Clipboard’ Initiative
eClinicalWorks announced production support for the CMS “Kill the Clipboard” initiative, enabling paper‑less patient intake through QR‑code scanning with its eClinicalMobile app. When patients arrive, a secure QR code pulls verified medical records from interoperability networks and populates the EHR...
I Tried Ozempic. This Is What You Need to Know.
A dietitian purchased Ozempic through an online telehealth service by simply misrepresenting her medical history, exposing how lax verification enables easy access to GLP‑1 drugs. She kept the medication in her fridge, later self‑administered a 0.25 mg dose, and reflected on...
AI-Driven Precision Care Is the Fix for Our Health System’s Failures
Primary care physicians face chronic time constraints, often resorting to rushed exams and delayed specialist referrals that exacerbate patient outcomes. AI‑driven precision care tools act as intelligent clinical assistants, surfacing relevant chart data, suggesting differential diagnoses, and drafting evidence‑based treatment...
Amazon Pharmacy to Offer Eli Lilly’s Foundayo via Same-Day Delivery
Amazon Pharmacy announced it will dispense Eli Lilly’s newly approved oral GLP‑1 drug Foundayo, a once‑daily treatment for obesity and overweight adults. Customers can order the medication with a prescription, view real‑time availability and transparent pricing, and receive same‑day delivery...
Office of Prescription Drug Promotion (OPDP) News
The FDA’s Office of Prescription Drug Promotion issued a final guidance on Jan 6 2025 that clarifies its enforcement policy for firm‑initiated communications of scientific information on unapproved uses (SIUU) to health‑care providers. The document specifies permissible source publications—journal reprints, clinical practice...